NVO vs. REGN

In the year-to-date period, NVO achieves a -2.11% return, which is significantly higher than REGN's -13.83% return. Over the past 10 years, NVO has outperformed REGN with an annualized return of 18.69%, while REGN has yielded a comparatively lower 6.25% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NVO Sharpe Ratio is 0.06, which is higher than the REGN Sharpe Ratio of -0.21. The chart below compares the historical Sharpe Ratios of NVO and REGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NVO's dividend yield for the trailing twelve months is around 1.44%, while REGN has not paid dividends to shareholders.

The maximum NVO drawdown since its inception was -71.30%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for NVO and REGN. For additional features, visit the drawdowns tool.

The current volatility for Novo Nordisk A/S (NVO) is 6.98%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 10.31%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.